The Role of Lytic Infection for Lymphomagenesis of Human γ-Herpesviruses.
Epstein Barr virus
Kaposi sarcoma associated herpesvirus
early lytic EBV antigen specific T cells
natural killer cells
viral G-protein coupled receptor
viral IL-10
viral IL-6
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
09
2020
accepted:
09
03
2021
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
17
6
2021
Statut:
epublish
Résumé
Epstein Barr virus (EBV) and Kaposi sarcoma associated herpesvirus (KSHV) are two oncogenic human γ-herpesviruses that are each associated with 1-2% of human tumors. They encode bona fide oncogenes that they express during latent infection to amplify their host cells and themselves within these. In contrast, lytic virus particle producing infection has been considered to destroy host cells and might be even induced to therapeutically eliminate EBV and KSHV associated tumors. However, it has become apparent in recent years that early lytic replication supports tumorigenesis by these two human oncogenic viruses. This review will discuss the evidence for this paradigm change and how lytic gene products might condition the microenvironment to facilitate EBV and KSHV associated tumorigenesis.
Identifiants
pubmed: 33842383
doi: 10.3389/fcimb.2021.605258
pmc: PMC8034291
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
605258Informations de copyright
Copyright © 2021 Münz.
Déclaration de conflit d'intérêts
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS Pathog. 2014 Aug 28;10(8):e1004333
pubmed: 25165855
Immunity. 2019 May 21;50(5):1305-1316.e6
pubmed: 30979688
Int J Cancer. 2019 Nov 1;145(9):2468-2477
pubmed: 31265124
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8
pubmed: 9751773
J Exp Med. 2013 Aug 26;210(9):1743-59
pubmed: 23897980
Blood. 2015 May 14;125(20):e14-22
pubmed: 25827832
Blood. 2016 Apr 21;127(16):2007-17
pubmed: 26744460
J Clin Invest. 2018 Jun 1;128(6):2519-2534
pubmed: 29733294
Blood Cancer J. 2016 Feb 26;6:e398
pubmed: 26918362
J Immunol. 2013 Dec 1;191(11):5398-409
pubmed: 24146041
Nat Commun. 2020 Jul 31;11(1):3849
pubmed: 32737300
Science. 2013 Jul 12;341(6142):186-91
pubmed: 23846901
Blood. 2005 May 15;105(10):3987-94
pubmed: 15665117
Blood. 1996 Jul 15;88(2):645-56
pubmed: 8695812
J Virol. 2004 Jan;78(2):768-78
pubmed: 14694109
Annu Rev Pathol. 2014;9:349-72
pubmed: 24111911
J Virol. 2003 Feb;77(4):2631-9
pubmed: 12552002
J Infect Dis. 2013 Jan 1;207(1):80-8
pubmed: 23100562
Blood. 2020 Feb 27;135(9):644-655
pubmed: 31942615
Immunol Rev. 2019 Sep;291(1):174-189
pubmed: 31402499
Front Oncol. 2019 Aug 06;9:713
pubmed: 31448229
Blood. 2008 Aug 15;112(4):1231-9
pubmed: 18519810
Cancer Lett. 2011 Jun 28;305(2):163-74
pubmed: 21493001
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11379-E11387
pubmed: 30429324
J Virol. 2011 Jan;85(1):165-77
pubmed: 20980506
J Immunol. 2014 May 15;192(10):4492-6
pubmed: 24740502
Nat Rev Microbiol. 2019 Nov;17(11):691-700
pubmed: 31477887
Semin Immunopathol. 2020 Apr;42(2):143-157
pubmed: 32219477
J Immunol. 2006 Oct 1;177(7):4897-906
pubmed: 16982932
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
Cell Mol Life Sci. 2020 Nov;77(21):4315-4324
pubmed: 32367191
J Clin Invest. 2020 Jan 2;130(1):507-522
pubmed: 31714901
J Natl Cancer Inst. 2002 Jun 19;94(12):926-35
pubmed: 12072546
PLoS Pathog. 2018 Dec 6;14(12):e1007464
pubmed: 30521644
Curr Opin Virol. 2015 Oct;14:138-44
pubmed: 26453799
PLoS One. 2018 Sep 28;13(9):e0204947
pubmed: 30265712
J Gen Virol. 2010 Mar;91(Pt 3):630-42
pubmed: 19923263
Cancer Res. 2007 Mar 1;67(5):2382-8
pubmed: 17332371
Blood. 2003 May 15;101(10):4115-21
pubmed: 12531789
Cell Host Microbe. 2017 Jul 12;22(1):61-73.e7
pubmed: 28704654
J Exp Med. 1998 May 4;187(9):1395-402
pubmed: 9565632
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
N Engl J Med. 2003 Oct 2;349(14):1324-32
pubmed: 14523140
Haematologica. 2019 Mar;104(3):564-575
pubmed: 30309853
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16519-16528
pubmed: 31363046
Nat Microbiol. 2019 Mar;4(3):404-413
pubmed: 30664667
J Clin Invest. 2001 Dec;108(12):1789-96
pubmed: 11748262
J Clin Immunol. 2015 Feb;35(2):112-8
pubmed: 25504528
J Clin Invest. 2016 Sep 1;126(9):3165-75
pubmed: 27584730
J Immunol. 2005 Mar 15;174(6):3686-94
pubmed: 15749907
J Virol. 2007 Jan;81(2):474-82
pubmed: 17079298
Oncogene. 2018 Jul;37(29):3998-4012
pubmed: 29691476
Nat Rev Dis Primers. 2019 Jan 31;5(1):9
pubmed: 30705286
Blood. 2012 May 31;119(22):5173-81
pubmed: 22490805
PLoS Pathog. 2018 Jul 27;14(7):e1007179
pubmed: 30052684
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Oncotarget. 2017 Nov 25;8(65):109402-109416
pubmed: 29312617
J Clin Invest. 2016 Oct 3;126(10):3772-3782
pubmed: 27571408
Front Immunol. 2019 Sep 18;10:2193
pubmed: 31620125
FEMS Microbiol Rev. 2019 Mar 1;43(2):181-192
pubmed: 30649299
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44
pubmed: 14688409
N Engl J Med. 2010 May 27;362(21):1993-2000
pubmed: 20505178
Annu Rev Immunol. 2015;33:787-821
pubmed: 25706097
J Clin Invest. 2019 May 1;129(5):2071-2087
pubmed: 31042161
Histol Histopathol. 2015 May;30(5):559-68
pubmed: 25301266
J Exp Med. 2006 Apr 17;203(4):805-8
pubmed: 16549599
J Virol. 2012 Aug;86(15):7976-87
pubmed: 22623780
PLoS Pathog. 2012;8(5):e1002704
pubmed: 22615564
mBio. 2019 Sep 17;10(5):
pubmed: 31530670
J Natl Cancer Inst. 2000 May 3;92(9):721-8
pubmed: 10793108
Nat Rev Immunol. 2001 Oct;1(1):75-82
pubmed: 11905817
Clin Immunol. 2015 Jul;159(1):58-62
pubmed: 25956530
Cell Rep. 2013 Dec 26;5(6):1489-98
pubmed: 24360958
Blood. 2007 Mar 1;109(5):2174-82
pubmed: 17090655
PLoS One. 2018 Nov 16;13(11):e0205632
pubmed: 30444879
Curr Opin Virol. 2021 Feb;46:1-8
pubmed: 32771660
Blood. 2004 Nov 1;104(9):2903-11
pubmed: 15231571
PLoS Pathog. 2014 May 22;10(5):e1004068
pubmed: 24853673
J Clin Virol. 2018 May;102:84-92
pubmed: 29525635
PLoS Pathog. 2015 Sep 01;11(9):e1005135
pubmed: 26327622
J Exp Med. 2000 Feb 7;191(3):445-54
pubmed: 10662790
Blood. 2013 Apr 11;121(15):2952-63
pubmed: 23365457
J Clin Immunol. 2017 Jan;37(1):32-35
pubmed: 27770395
Br J Haematol. 2005 Apr;129(2):266-74
pubmed: 15813855
Cell. 2015 Aug 27;162(5):1090-100
pubmed: 26279189
Vaccine. 2007 Jun 11;25(24):4697-705
pubmed: 17485150
Curr Opin Virol. 2018 Oct;32:15-23
pubmed: 30227386
J Clin Immunol. 2020 Jul;40(5):671-681
pubmed: 32451662
J Clin Invest. 2006 May;116(5):1264-73
pubmed: 16604194
J Virol. 2011 Dec;85(24):13105-13
pubmed: 21994444
Int J Cancer. 2006 Jun 15;118(12):3030-44
pubmed: 16404738
Cancer Cell. 2003 Jan;3(1):23-36
pubmed: 12559173
Blood. 2010 Nov 18;116(20):4158-67
pubmed: 20671122
Blood. 2014 Oct 16;124(16):2533-43
pubmed: 25205117
Adv Virol. 2010;2010:340356
pubmed: 22331985
Blood. 2013 Jun 20;121(25):5034-44
pubmed: 23482932
Elife. 2019 Apr 16;8:
pubmed: 30990165
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893942
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6400-5
pubmed: 20308568